GENE ONLINE|News &
Opinion
Blog

2021-09-11| Asia-Pacific

Korea’s First Private-Led New Drug Cluster to Launch in Late September

by Tyler Chen
Share To
Photo: Woojung Bio

South Korea’s CRO firm Woojung Bio planned on launching the first private-led new drug cluster in Korea at the end of September. The goal is to elevate Korean biotech’s ability to develop innovative drugs in the highly competitive market.

Provide R&D Infrastructures and Clinical Consulting Services

 

As the building will finish construction in late September, the cluster is expected to provide R&D infrastructures, analysis centers, and consulting services from nonclinical trials to clinical trials. Woojung Bio said the private-led cluster is able to work closely with the biotechs and move faster and more flexibly than the government-led cluster.

Partnering Up with Former Deputy Director of the USFDA

 

Since 2018, Woojung Bio has signed MOUs with 28 companies and institutions for the cluster. A few days ago, the firm penned an MOU with Ahn Bio Consulting, a powerhouse in clinical trials consultation for all stages of drug development and licensing. Its founder Hae Young Ahn is a former and the first Korean deputy director of the USFDA.

Ahn Bio Consulting is able to provide critical regulatory strategies in new medicine, the collaboration will also discover and cultivate domestic bio startups.

Other MOUs Signed

 

In late August, Woojung Bio struck a deal with Medirama to establish a bio cooperative system. Other than providing clinical consultation, the two firms will work together to eliminate drug candidates that failed to meet the criteria and help biotechs to expand their business to overseas countries.

Moreover, the collaboration will build an animal center and research center in the about-to-established cluster.

Woojung Bio also approached venture capitals, including Daily Partners, Spring Camp, Samho Green Investment, and bio associations such as Korea Biotechnology Association and Korea New Drug Development Research Association to form a more wholesome ecosystem in the cluster.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
R&D
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
2024-02-21
AstraZeneca’s severe asthma drug Tezspire has been granted market authorization in South Korea
2023-12-25
LATEST
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top